Ani Eloyan
YOU?
Author Swipe
View article: TRAECR: A Tool for Preprocessing Positron Emission Tomography Imaging for Statistical Modeling
TRAECR: A Tool for Preprocessing Positron Emission Tomography Imaging for Statistical Modeling Open
Positron emission tomography (PET) imaging is widely used in a number of clinical applications, including cancer and Alzheimer's disease (AD) diagnosis, monitoring of disease development, and treatment effect evaluation. Statistical modeli…
View article: Geometric Modeling of Hippocampal Tau Deposition: A Surface-Based Framework for Covariate Analysis and Off-Target Contamination Detection
Geometric Modeling of Hippocampal Tau Deposition: A Surface-Based Framework for Covariate Analysis and Off-Target Contamination Detection Open
We introduce a framework combining geometric modeling with disease progression analysis to investigate tau deposition in Alzheimer's disease (AD) using positron emission tomography (PET) data. Focusing on the hippocampus, we construct a pr…
View article: Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias
Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias Open
Early detection of Alzheimer's disease (AD) is critical yet challenging, particularly in younger individuals. This study leverages artificial intelligence to analyze digital voice recordings from the Craft Story Recall task within the Long…
View article: Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials
Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials Open
View article: Alzheimer’s Disease Polygenic Risk in the LEADS Cohort
Alzheimer’s Disease Polygenic Risk in the LEADS Cohort Open
Background Currently, it is unclear to what extent late‐onset Alzheimer’s disease (AD) risk variants contribute to early‐onset AD (EOAD). One method to clarify the contribution of late‐onset AD genetic risk to EOAD is to investigate the as…
View article: Utility of CSF biomarkers in assessing neurodegeneration in Early‐Onset Alzheimer’s disease
Utility of CSF biomarkers in assessing neurodegeneration in Early‐Onset Alzheimer’s disease Open
Background There is a significant need for biomarkers of neurodegenerative burden in Early‐onset Alzheimer’s disease (EOAD). Evidence suggests that levels of specific CSF biomarkers (e.g., Neurofilament light (NfL), Synaptosomal‐Associated…
View article: Association Between Age and Cognitive Severity in Early‐Onset AD: Extension of preliminary findings in the Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS)
Association Between Age and Cognitive Severity in Early‐Onset AD: Extension of preliminary findings in the Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS) Open
Background Widespread cognitive impairments have previously been documented in Early‐Onset Alzheimer’s Disease (EOAD) relative to cognitively normal (CN) same‐aged peers or those with cognitive impairment without amyloid pathology (Early‐O…
View article: A harmonized memory composite score for cross‐cohort Alzheimer’s disease and related dementia research: development and validation
A harmonized memory composite score for cross‐cohort Alzheimer’s disease and related dementia research: development and validation Open
Background The Uniform Data Set (UDS) neuropsychological battery, administered across Alzheimer’s Disease Centers (ADC), includes memory tests but lacks a list‐learning paradigm. ADCs often supplement the UDS with their own preferred list‐…
View article: Dissociable spatial topography of neurodegeneration in Early‐onset and Late‐onset Alzheimer’s Disease: A head‐to‐head comparison of MRI‐derived atrophy measures between the LEADS and ADNI cohorts
Dissociable spatial topography of neurodegeneration in Early‐onset and Late‐onset Alzheimer’s Disease: A head‐to‐head comparison of MRI‐derived atrophy measures between the LEADS and ADNI cohorts Open
Background Understanding how early‐onset Alzheimer’s disease (EOAD) differs from typical late‐onset AD (LOAD) is an important goal of AD research that may help increase the sensitivity of unique biomarkers for each phenotype. Building upon…
View article: Recurring genetic variant in LEADS
Recurring genetic variant in LEADS Open
Background The Longitudinal Early‐onset Alzheimer’s Disease Study (LEADS) is analyzing the genetic etiology of early onset (40‐64 years) cognitive impairment, including amyloid‐positive early‐onset Alzheimer’s disease (EOAD) and amyloid‐ne…
View article: Longitudinal neurodegeneration in Early‐Onset Alzheimer’s Disease: A summary of MRI‐derived atrophy in LEADS
Longitudinal neurodegeneration in Early‐Onset Alzheimer’s Disease: A summary of MRI‐derived atrophy in LEADS Open
Background Prior work has advanced our understanding of cortical atrophy in early‐onset Alzheimer’s disease (EOAD), but longitudinal data are sparse. Current longitudinal MRI studies point to progressive atrophy in cerebral cortex exhibiti…
View article: Longitudinal cognitive trajectories in sporadic early‐onset Alzheimer’s Disease: Findings from LEADS
Longitudinal cognitive trajectories in sporadic early‐onset Alzheimer’s Disease: Findings from LEADS Open
Background Early Onset Alzheimer’s Disease (EOAD) is a rare condition that manifests prior to the age of 65, and affects approximately 5% of patients with Alzheimer’s disease. The Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS) …
View article: Dissociable spatial topography of neurodegeneration in Early‐onset and Late‐onset Alzheimer’s Disease: A head‐to‐head comparison of MRI‐derived atrophy measures between the LEADS and ADNI cohorts
Dissociable spatial topography of neurodegeneration in Early‐onset and Late‐onset Alzheimer’s Disease: A head‐to‐head comparison of MRI‐derived atrophy measures between the LEADS and ADNI cohorts Open
Background Understanding how early‐onset Alzheimer’s disease (EOAD) differs from typical late‐onset AD (LOAD) is an important goal of AD research that may help increase the sensitivity of unique biomarkers for each phenotype. Building upon…
View article: Identifying anatomical subtypes of sporadic EOAD in LEADS via unsupervised clustering of MRI‐based regional atrophy patterns
Identifying anatomical subtypes of sporadic EOAD in LEADS via unsupervised clustering of MRI‐based regional atrophy patterns Open
Background Neurodegeneration in sporadic early‐onset Alzheimer disease (EOAD) is topographically heterogeneous, as suggested by variability in syndromic presentation. We performed an unsupervised clustering analysis of structural MRI data …
View article: Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort
Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort Open
Background Diagnosing sporadic early‐onset AD (EOAD, age‐at‐onset<65) is challenging: in the multi‐center Longitudinal Early‐onset Alzheimer’s Disease Study, ∼25% of patients with clinically diagnosed EOAD are amyloid‐PET‐negative. Here we…
View article: Heterogeneous clinical phenotypes of sporadic Early‐onset Alzheimer’s disease: A data‐driven approach
Heterogeneous clinical phenotypes of sporadic Early‐onset Alzheimer’s disease: A data‐driven approach Open
Background Early‐onset Alzheimer’s disease (EOAD) manifests prior to the age of 65. Clinical presentation of EOAD is distinct from that of late‐onset Alzheimer’s disease, and is characterized as having a more aggressive disease course with…
View article: Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts
Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts Open
Background Large‐scale studies comparing sporadic early‐onset AD (EOAD, age<65) and late‐onset AD (LOAD, age = 65) are lacking. We compared amyloid‐PET outcomes (positivity rate and amyloid burden) between patients clinically diagnosed wit…
View article: Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts
Amyloid‐PET in patients with a clinical diagnosis of sporadic early‐ versus late‐onset AD: comparison of the LEADS and ADNI cohorts Open
Background Large‐scale studies comparing sporadic early‐onset AD (EOAD, age<65) and late‐onset AD (LOAD, age≥65) are lacking. We compared amyloid‐PET outcomes (positivity rate and amyloid burden) between patients clinically diagnosed with …
View article: Effects of BDNF and COMT variants on cognitive decline in Early‐Onset Alzheimer’s Disease
Effects of BDNF and COMT variants on cognitive decline in Early‐Onset Alzheimer’s Disease Open
Background Early‐Onset Alzheimer’s Disease (EOAD) is a rare condition that affects only 5% of patients with Alzheimer’s Disease (AD). At present, only basic information is known about the impact of AD risk variants on EOAD, and the effects…
View article: Effects of APOE genotype on cortical atrophy in early onset Alzheimer’s disease
Effects of APOE genotype on cortical atrophy in early onset Alzheimer’s disease Open
Background APOE‐ɛ4 is a major risk factor for Alzheimer’s disease (AD); its effects have been examined in late‐onset AD (LOAD) but less so in early‐onset AD (EOAD). In LOAD, APOE genotype has strong effects on episodic memory and medial te…
View article: Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort
Characterization of the heterogeneity of amyloid‐PET‐negative patients with a clinical diagnosis of sporadic early‐onset AD: an FDG‐PET study in the LEADS cohort Open
Background Diagnosing sporadic early‐onset AD (EOAD, age‐at‐onset<65) is challenging: in the multi‐center Longitudinal Early‐onset Alzheimer’s Disease Study, ∼25% of patients with clinically diagnosed EOAD are amyloid‐PET‐negative. Here we…
View article: Cognitive clusters in sporadic early‐onset Alzheimer’s disease patients from the LEADS study
Cognitive clusters in sporadic early‐onset Alzheimer’s disease patients from the LEADS study Open
Background Early‐onset Alzheimer’s disease (EOAD) occurs before age 65 and has more diverse disease presentations than late‐onset AD. To improve our understanding of phenotypic heterogeneity among EOAD individuals, we analyzed cognitive sc…
View article: Randomness of Shapes and Statistical Inference on Shapes via the Smooth Euler Characteristic Transform
Randomness of Shapes and Statistical Inference on Shapes via the Smooth Euler Characteristic Transform Open
In this article, we establish the mathematical foundations for modeling the randomness of shapes and conducting statistical inference on shapes using the smooth Euler characteristic transform. Based on these foundations, we propose two chi…
View article: Midpoint baseline results of the Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS)
Midpoint baseline results of the Longitudinal Early‐Onset Alzheimer’s Disease Study (LEADS) Open
Background Fewer than 5% of patients with Alzheimer’s disease are diagnosed between 40‐64 years old, making “early‐onset Alzheimer’s disease” (EOAD) an uncommon phenomenon (Zu et al., 2015). To date, only basic knowledge on EOAD is known, …
View article: Parkinson’s Disease Genetic Variants in Sporadic Early Onset Dementia: Results from the Longitudinal Early Onset Alzheimer’s Disease Study
Parkinson’s Disease Genetic Variants in Sporadic Early Onset Dementia: Results from the Longitudinal Early Onset Alzheimer’s Disease Study Open
Background Much of the genetic etiology of sporadic early onset Alzheimer’s disease and frontotemporal dementia is largely unknown. Genetic investigation using whole exome sequencing (WES) data in the Longitudinal Early Onset Alzheimer’s D…
View article: Investigating the Genetics of Sporadic Early‐Onset Alzheimer’s Disease
Investigating the Genetics of Sporadic Early‐Onset Alzheimer’s Disease Open
Background Only a small percentage of early‐onset Alzheimer’s disease (EOAD) participants are known to carry autosomal dominant pathogenic variants in the amyloid beta precursor protein (APP) gene or in presenilin 1 or 2 (PSEN1/2); more re…
View article: Sex‐associated differences in plasma and cerebrospinal fluid biomarkers in Early‐onset Alzheimer’s disease
Sex‐associated differences in plasma and cerebrospinal fluid biomarkers in Early‐onset Alzheimer’s disease Open
Background Female sex is associated with greater atrophy, amyloid and tau burden in Early‐onset Alzheimer’s Disease (EOAD) in the Longitudinal EOAD Study (LEADS). APOE‐ε4 non‐carrier‐status was found to be a further predictor of EOAD patho…
View article: Amyloid‐PET, tau‐PET, and their association in sporadic early‐onset Alzheimer’s Disease: Cross‐sectional and longitudinal data from the LEADS study
Amyloid‐PET, tau‐PET, and their association in sporadic early‐onset Alzheimer’s Disease: Cross‐sectional and longitudinal data from the LEADS study Open
Background We aimed to describe amyloid‐ and tau‐PET in patients with sporadic Early Onset AD (sEOAD) from the Longitudinal Early‐onset Alzheimer’s Disease Study. We focused on amyloid‐tau relationships and on the association between i) ag…
View article: Association Between Age and Cognitive Severity in Participants from the Longitudinal Early‐Onset Alzheimer’s Disease Study
Association Between Age and Cognitive Severity in Participants from the Longitudinal Early‐Onset Alzheimer’s Disease Study Open
Background Age‐related cognitive declines are well‐documented in cognitively normal adults (van der Willik et al., 2021), as are greater cognitive impairments with advancing age in traditional‐ (or “late‐”) onset Alzheimer’s disease (LOAD;…
View article: Regional patterns of pathological tau accumulation in sporadic early‐onset Alzheimer’s disease: Longitudinal tau‐PET in the LEADS Cohort
Regional patterns of pathological tau accumulation in sporadic early‐onset Alzheimer’s disease: Longitudinal tau‐PET in the LEADS Cohort Open
Background The longitudinal progression of tau pathology in sporadic early‐onset Alzheimer’s disease (EOAD, age‐at‐onset<65) has not been well established and may be key to its understanding and treatment. We utilized in vivo PET imaging t…